Clinical Trial Update: Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study [Phase 1]

View source ↗

Summary

A Phase I dose-escalation study of a SARS-CoV recombinant S protein vaccine, with and without an adjuvant, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• SARS-CoV Recombinant S Protein Vaccine (recombinant SARS-CoV spike (S) protein vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: SARS | Phase 1 | Status: WITHDRAWN